30-day average of 6 articles Β· scale β100 to +100
Across 6 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Zoetis news is Somewhat Bearish (-28)
on a scale from β100 to +100.
π Stock trades at 13.5x earnings after losing 29.6% over the past year.
Somewhat Bearish -40
Should You Buy Zoetis Stock At This Price?
AI-generated analysis
Key insights
π Zoetis stock trades at a 13.5x earnings multiple, significantly below the 22.3x median for S&P 500 companies after losing 29.6% over the past year.
π° The company maintains an operating margin of 37.7%, outpacing the 19.0% S&P 500 median, indicating strong pricing power despite lower revenue growth.
π Revenue growth has nearly stalled at 0.9% in the latest quarter, down from a 4.3% average over the previous three twelve-month periods.
π Dermatology sales fell 16% worldwide in the quarter as key products like Apoquel lost market share to generic competition.
π Management narrowed fiscal 2026 revenue guidance to an organic decline of 1% to 2%, expecting limited impact from new launches until late 2027.
πΈ Net income dropped to $2.51 billion from $2.63 billion a year earlier, even as operating income rose.
π Operating cash flow fell to $2.73 billion from $2.96 billion in the prior year period.
π¬ Zoetis is introducing more convenient versions of pet medicines and offering discounts to slow the loss of U.S. dermatology market share.
π The company expects U.S. approval in the fourth quarter for long-acting Cytopoint, a chronic itch treatment for pets.
π Investors buying at current prices are betting on Zoetis fixing its real sales problem rather than simply owning a sound but non-growing business.
π Bullish signals
π°Zoetis maintains an operating margin of 37.7% over the four quarters ended September 2026, significantly outpacing the 19.0% median for S&P 500 companies.
πThe company trades at a discount on cash flow, priced at 12.4 times operating cash flow versus 14.9 for the S&P 500 as a whole.
π Risk factors
πRevenue growth has nearly stopped, expanding by only 0.9% over the four quarters ended September 2026, lagging the 4.3% average across the latest three periods.
πDermatology sales fell 16% worldwide in the quarter as key products like Apoquel lost market share to generic competition.
πΈNet income dropped to $2.51 billion from $2.63 billion a year earlier, even though operating income rose.
Article
Zoetis (ZTS) stock is currently trading at a significant discount to the S&P 500 median, with a price-to-earnings multiple of 13.5 compared to 22.3 for the broader index. Over the past twelve months, shares have declined by 29.6%, leading some analysts to question whether the market assumes the company has ceased growth. The article investigates if this valuation gap represents a buying opportunity or reflects genuine fundamental deterioration in Zoetis's business model.
Despite the lower valuation, Zoetis maintains robust profitability with an operating margin of 37.7% over the four quarters ended September 2026, significantly outpacing the S&P 500 median of 19.0%. The company also trades at a discount on cash flow, priced at 12.4 times operating cash flow versus 14.9 for the broader market. However, net income and operating cash flow have recently declined, with net income falling to $2.51 billion from $2.63 billion in the prior year.
Revenue growth has nearly stalled, expanding by only 0.9% in the latest quarter compared to a 4.3% average over the previous three periods. The primary driver of this slowdown is a decline in dermatology medicines, which lost 16% worldwide in the most recent quarter as key products like Apoquel lost market share to generic competition. Management has narrowed its fiscal 2026 revenue guidance to an organic decline of 1% to 2%, projecting limited impact from new product launches until late 2027.
Investors buying Zoetis at current prices are effectively betting that the company can fix its sales issues while maintaining high profit margins. The stock appears to already price in a scenario where Zoetis owns a highly profitable but non-growing business. Key metrics to watch include fourth-quarter dermatology sales, which are expected to be reported in February 2027, as well as the success of new launches like long-acting Cytopoint.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Zoetis (ZTS) stock is currently trading at a significant discount to the S&P 500 median, with a price-to-earnings multiple of 13.5 compared to 22.3 for the broader index. Over the past twelve months, shares have declined by 29.6%, leading some analysts to question whether the market assumes the company has ceased growth. The article investigates if this valuation gap represents a buying opportunity or reflects genuine fundamental deterioration in Zoetis's business model.
Despite the lower valuation, Zoetis maintains robust profitability with an operating margin of 37.7% over the four quarters ended September 2026, significantly outpacing the S&P 500 median of 19.0%. The company also trades at a discount on cash flow, priced at 12.4 times operating cash flow versus 14.9 for the broader market. However, net income and operating cash flow have recently declined, with net income falling to $2.51 billion from $2.63 billion in the prior year.
Revenue growth has nearly stalled, expanding by only 0.9% in the latest quarter compared to a 4.3% average over the previous three periods. The primary driver of this slowdown is a decline in dermatology medicines, which lost 16% worldwide in the most recent quarter as key products like Apoquel lost market share to generic competition. Management has narrowed its fiscal 2026 revenue guidance to an organic decline of 1% to 2%, projecting limited impact from new product launches until late 2027.
Investors buying Zoetis at current prices are effectively betting that the company can fix its sales issues while maintaining high profit margins. The stock appears to already price in a scenario where Zoetis owns a highly profitable but non-growing business. Key metrics to watch include fourth-quarter dermatology sales, which are expected to be reported in February 2027, as well as the success of new launches like long-acting Cytopoint.
π Stock trades at 13.5x earnings after losing 29.6% over the past year.
π Dermatology sales fell 16% as key products lost market share to generics.
π Management narrowed guidance to an organic revenue decline of 1% to 2%.
π Long-acting Cytopoint expected for U.S. approval in the fourth quarter.
π Zoetis stock trades at a 13.5x earnings multiple, significantly below the 22.3x median for S&P 500 companies after losing 29.6% over the past year.
π° The company maintains an operating margin of 37.7%, outpacing the 19.0% S&P 500 median, indicating strong pricing power despite lower revenue growth.
π Revenue growth has nearly stalled at 0.9% in the latest quarter, down from a 4.3% average over the previous three twelve-month periods.
π Dermatology sales fell 16% worldwide in the quarter as key products like Apoquel lost market share to generic competition.
π Management narrowed fiscal 2026 revenue guidance to an organic decline of 1% to 2%, expecting limited impact from new launches until late 2027.
πΈ Net income dropped to $2.51 billion from $2.63 billion a year earlier, even as operating income rose.
π Operating cash flow fell to $2.73 billion from $2.96 billion in the prior year period.
π¬ Zoetis is introducing more convenient versions of pet medicines and offering discounts to slow the loss of U.S. dermatology market share.
π The company expects U.S. approval in the fourth quarter for long-acting Cytopoint, a chronic itch treatment for pets.
π Investors buying at current prices are betting on Zoetis fixing its real sales problem rather than simply owning a sound but non-growing business.
Bullish Signals
Operating margin of 37.7% outpaces S&P 500 median of 19.0%.
Trades at 12.4x operating cash flow vs 14.9x S&P 500.
Risk Factors
Revenue growth stalled at 0.9% over four quarters ended Sep 2026.
Dermatology sales fell 16% worldwide as Apoquel lost market share.
Net income dropped to $2.51 billion despite rising operating income.
Bullish Signals
Zoetis maintains an operating margin of 37.7% over the four quarters ended September 2026, significantly outpacing the 19.0% median for S&P 500 companies.
The company trades at a discount on cash flow, priced at 12.4 times operating cash flow versus 14.9 for the S&P 500 as a whole.
Risk Factors
Revenue growth has nearly stopped, expanding by only 0.9% over the four quarters ended September 2026, lagging the 4.3% average across the latest three periods.
Dermatology sales fell 16% worldwide in the quarter as key products like Apoquel lost market share to generic competition.
Net income dropped to $2.51 billion from $2.63 billion a year earlier, even though operating income rose.
Zoetis Inc. (NYSE: ZTS) has experienced a sharp decline in valuation, losing over half its value and trading at a forward P/E of approximately 12x compared to 21.69x a year ago. This significant drop is driven by weaker demand in its U.S. companion-animal business, which pressured earnings forecasts and caused the stock price to fall more than 45% over the past 12 months.
The company reported second-quarter 2026 revenue of $2.5 billion, essentially flat year-over-year, with organic operational revenue declining by 1%. Adjusted diluted EPS was $1.87, while adjusted net income declined by 2%. Consequently, Zoetis has materially reduced its full-year 2026 guidance, expecting organic operational revenue growth of (3)% to (1)% and adjusted diluted EPS between $6.15 and $6.25.
The primary headwind is concentrated in the U.S. companion-animal market, where revenue fell 7% in the second quarter due to lower clinic visits, price sensitivity among pet owners, and heightened competition from generic products like Cerenia and Convenia. However, the company shows resilience in other segments, with U.S. livestock product sales increasing 23% and international revenue rising 8% on a reported basis.
Zoetis maintains long-term growth potential through its pipeline of over 12 potential blockbuster candidates targeting areas such as chronic kidney disease, oncology, and cardiology. Additionally, the company is expanding its diagnostics business following the acquisition of VitalRADS and has received regulatory approvals for new products like Dectomax-CA1 to address specific animal health threats.
π Zoetis shares dropped 45% as U.S. companion-animal demand pressured results.
π° Stock trades at 12x forward P/E, down from 21.69x last September.
π Q2 2026 revenue was $2.5B flat with organic decline of 1%.
π Livestock sales surged 23% driven by strong cattle and poultry demand.
π Pipeline holds 12+ candidates for kidney disease, oncology, and obesity.
π Zoetis shares have dropped over 45% in the past year as weaker U.S. companion-animal demand pressured results and revised earnings forecasts.
π° The stock now trades at a forward P/E of approximately 12x, down from 21.69x as of September 30, 2025, reflecting a much cheaper valuation.
π Second-quarter 2026 revenue was $2.5 billion, essentially flat year-over-year, with organic operational revenue declining by 1%.
π Zoetis revised its full-year 2026 guidance to expect organic operational revenue growth of (3)% to (1)% and adjusted diluted EPS of $6.15 to $6.25.
πΎ U.S. companion-animal product sales fell 11% in the second quarter due to lower clinic visits, price sensitivity, and generic competition affecting products like Cerenia.
π Livestock products provided a bright spot with U.S. sales increasing 23%, supported by cattle and poultry demand.
π International revenue rose 8% on a reported basis and 6% organically, while international companion-animal product sales increased 5% organically.
π Zoetis has more than 12 potential blockbuster candidates in its pipeline targeting chronic kidney disease, oncology, cardiology, anxiety, and obesity.
π¬ The company completed the acquisition of VitalRADS to expand its veterinary teleradiology platform into diagnostics.
β Dectomax-CA1 received FDA conditional approval for preventing and treating screwworm myiasis in beef cattle.
Bullish Signals
Forward P/E dropped to 12x from 21.69x.
U.S. livestock sales surged 23% in Q2.
International revenue rose 8% organically.
Pipeline has 12+ candidates for high-value diseases.
Acquired VitalRADS to expand diagnostics.
Dectomax-CA1 got FDA approval for new use.
Risk Factors
Reduced 2026 earnings expectations due to conservative growth view.
U.S. revenue fell 7% Q2; companion sales down 11%.
Organic revenue -1%; adjusted net income -2% slowdown.
Generic competition eroding Cerenia/Convenia share and pricing.
Bullish Signals
Zoetis trades at a significantly lower forward P/E of approximately 12x compared to 21.69x a year ago, offering a cheaper valuation despite the slowdown.
U.S. sales of livestock products increased 23% in the second quarter, supported by strong demand for cattle and poultry products.
International revenue rose 8% on a reported basis and 6% organically, demonstrating resilience outside the struggling U.S. companion-animal market.
The company possesses a robust pipeline with more than 12 potential blockbuster candidates targeting high-value areas like oncology, cardiology, and chronic kidney disease.
Zoetis successfully expanded its diagnostics business by acquiring VitalRADS to enhance veterinary imaging interpretation capabilities.
Dectomax-CA1 received FDA conditional approval for a new indication in beef cattle, highlighting the strategic relevance of its existing portfolio.
Risk Factors
Zoetis has materially reduced its 2026 earnings expectations, signaling a more conservative view of future growth due to current market conditions.
U.S. revenue declined 7% in the second quarter, with companion-animal product sales falling 11% due to lower clinic visits and price sensitivity.
Organic operational revenue declined by 1% and adjusted net income fell by 2%, indicating a meaningful slowdown in core business performance.
Generic competition is weighing on key products like Cerenia and Convenia, eroding market share and pricing power in the companion-animal segment.
Zoetis (ZTS) shares dropped approximately 3% on the first trading day following its Q3 2026 earnings release, as investors reacted to significant pressure on profitability and softer full-year guidance. Quarterly net income excluding extra items fell to US$591 million from US$721 million in the prior year, while basic EPS declined to US$1.44 from US$1.63. The market's sharp reaction reflects concerns that the company's steady franchise status is being challenged by recent financial headwinds.
The core issue driving the stock decline is a compression in adjusted gross margins, which stood at approximately 71% and represented an operational decline of about 0.6 percentage points year over year. Despite flat operating costs on an adjusted basis, Zoetis saw its adjusted net income decline by 7% organically. This divergence highlights that cost control measures alone are insufficient to bridge the gap created by revenue softness in key segments.
Zoetis faces specific headwinds in its companion animal business, where total revenue fell 5% and dermatology sales plummeted 16%. Management emphasizes the critical need to offset competitive pressure and pricing issues in U.S. companion animal therapies by scaling new products and maintaining momentum in livestock and diagnostics. While these latter segments showed growth with livestock up 7% and diagnostics rising 13%, they have not yet been large enough to neutralize the broader pressures affecting the company's bottom line.
π Zoetis shares fell 3% after Q3 earnings due to lower profitability and softer guidance.
π° Quarterly net income dropped 18% year-over-year to US$591 million, missing market expectations.
π Adjusted gross margins compressed to 71%, reflecting operational decline of 0.6 percentage points.
β οΈ Analysts worry growing segments cannot yet offset core business pressures and lost market share.
π Zoetis shares dropped about 3% immediately after Q3 2026 earnings, driven by a sharp decline in profitability and softer full-year guidance.
π° Quarterly net income excluding extra items fell to US$591 million, representing an 18.0% year-over-year decrease compared to US$721 million last year.
π Basic EPS declined to US$1.44 from US$1.63 in the prior year, marking an 11.8% drop that contributed to the negative market reaction.
π Adjusted gross margins compressed to approximately 71%, reflecting an operational decline of about 0.6 percentage points year over year.
πΎ Companion animal revenue fell 5% overall, with dermatology sales specifically dropping 16% despite improved guidance for that segment.
π¬ Diversification efforts showed mixed results as livestock revenue climbed 7% and diagnostics rose 13% to partially offset companion animal weakness.
βοΈ Adjusted net income declined 7% organically, indicating that flat operating costs were not enough to counteract the revenue headwinds.
π Management stated that scaling new products is essential to offset competitive and pricing pressure in U.S. companion animal therapies.
π The company must convert its broad pipeline in areas like renal disease, oncology, and cardiology into products to replace lost share from existing cash engines.
β οΈ Bearish analysts remain concerned that offsets from growing segments are not yet large enough to neutralize the pressures facing the core business.
Bullish Signals
Livestock revenue climbed 7% year over year.
Diagnostics sales rose 13%.
Operating costs remained flat on an adjusted basis.
Risk Factors
Net income excluding items dropped 18.0% to US$591 million.
Adjusted gross margins compressed 0.6 percentage points to 71%.
Six major institutional funds, including Fundsmith and Veritas Asset Management, significantly reduced or completely exited their positions in Zoetis (ZTS) during the quarter ended June 30. Fundsmith sold its entire stake of 3.88 million shares, while others like Polen Capital and Unisphere Establishment cut holdings by over 45%. This selling activity coincides with a broader decline in ZTS stock, which has fallen approximately 30% from its March highs.
The primary driver for the institutional outflows is Zoetis's deteriorating earnings outlook. The company has issued two guidance cuts this year, most recently lowering its 2026 adjusted EPS forecast to $6.15-$6.25 and predicting a slight decline in organic revenue of 1% to 3%. Management attributes these challenges to softer US demand, specifically fewer veterinary visits and increased price sensitivity among pet owners.
Despite the negative sentiment and guidance cuts, Zoetis currently trades at a forward P/E ratio of roughly 13.5x, which is less than half its five-year average of 28x. The stock also trades at a discount compared to peers like Takeda and United Therapeutics. Analysts have adjusted their targets downward, with the average price target falling to $88, though the current share price remains slightly above this consensus.
The article highlights an upcoming earnings report on November 5 as a critical juncture for investors. While some view the current valuation as attractive given the 43% drop from highs, there is a risk of a third guidance cut if demand continues to slip. The author suggests holding or buying if the company can maintain its revised guidance through the upcoming quarter.
π Major funds reduced Zoetis stakes in Q2 amid softer US demand.
π Management cut 2026 guidance twice due to fewer vet visits.
π° Stock trades at 13.5x forward earnings, below five-year average.
π Shares fell 30% from March but remain up 17% from June.
π Six major funds, including Fundsmith and Veritas Asset Management, sold or significantly reduced their Zoetis stakes in the quarter ended June 30.
π Zoetis has cut its 2026 earnings guidance twice this year, with analysts now expecting a dip in earnings for the current fiscal year.
π° The stock trades at approximately 13.5x forward earnings, which is less than half of its five-year average valuation multiple.
π Management cited softer US demand, including fewer vet visits and price-conscious pet owners, as reasons for the recent guidance reductions.
π Zoetis stock has fallen roughly 30% from its March 31 price but remains up 17% from where it ended June.
π Analysts have lowered their average price target to $88, reflecting concerns over the company's near-term growth trajectory.
β οΈ Investors face the risk of a third guidance cut when Zoetis reports Q3 results on November 5 if demand continues to weaken.
π Despite the sell-off, the current valuation is significantly lower than peers like Takeda Pharmaceutical and United Therapeutics.
Bullish Signals
Trades at 13.5x forward P/E, half its 28x five-year average.
Trades below peers Takeda and United Therapeutics on valuation.
Price above lowest analyst target of $74.
Risk Factors
Cut 2026 guidance twice; analysts expect current fiscal earnings decline.
Bullish Signals
The stock trades at a forward P/E of roughly 13.5x, which is less than half its five-year average of 28x.
Zoetis currently trades below peer specialty drugmakers like Takeda Pharmaceutical and United Therapeutics on a valuation basis.
The current share price sits slightly above the lowest analyst price target of $74, despite the consensus target being lower.
Risk Factors
Zoetis has cut its 2026 earnings guidance twice this year, with analysts now expecting a decline in earnings for the current fiscal year.
Management lowered its 2026 adjusted EPS guidance to $6.15-$6.25 and forecasts organic revenue to fall 1% to 3% this year.
The company attributes recent performance issues to softer US demand, specifically fewer vet visits and pet owners being more careful about price.
Six major funds, including Fundsmith which sold out completely, have exited or significantly reduced their positions in the quarter ended June 30.
Analysts have aggressively cut their price targets, with the average falling from $188 a year ago to $88.
Zoetis (ZTS) received FDA approval for Convenia RTU, a ready-to-use antibiotic for dogs, on October 20, 2026. This new product adds to the company's companion-animal portfolio by offering up to 14 days of treatment from a single injection for bacterial skin infections like pyoderma and abscesses. The product is expected to reach veterinarians in the first quarter of 2027.
Financially, Zoetis reported strong second-quarter 2026 performance with revenue reaching USD 2.47 billion and diluted earnings per share of USD 1.65. The company also declared a quarterly dividend of USD 0.53 on October 8, 2026, with a record date set for October 30, 2026. These figures highlight the robust cash flow supporting shareholder returns despite market headwinds.
Despite the product expansion, analyst sentiment has turned cautious due to pricing pressures and competitive risks in the sector. Jefferies downgraded its rating on Zoetis from Buy to Hold and cut its price target from USD 103 to USD 83 on October 20, 2026. The company is preparing to release third-quarter results on November 5, 2026, which will likely reflect the ongoing balance between pipeline growth and margin challenges.
π FDA approved Convenia RTU for dogs on October 20, 2026.
π New product offers up to 14 days of antibiotic coverage.
π Launch expected with veterinarians in first quarter of 2027.
π° Q2 2026 revenue reached USD 2.47 billion.
π Diluted EPS for Q2 2026 were USD 1.65.
π FDA approved Convenia RTU for dogs on October 20, 2026, expanding Zoetis' companion-animal portfolio with a ready-to-use antibiotic.
π The new Convenia RTU product provides up to 14 days of antibiotic coverage from a single injection for bacterial skin infections.
π Zoetis is expected to launch the new antibiotic product with veterinarians in the first quarter of 2027.
Goldman Sachs initiated coverage of Zoetis (ZTS) on October 17, 2026, assigning a Hold rating and a USD 74.00 price target. This target sits below the stock's recent trading price of approximately USD 79.32 as of mid-October, suggesting a neutral-to-negative near-term outlook from the analyst firm.
Zoetis reported second-quarter 2026 revenue of USD 2.47 billion on August 6, accompanied by a decline in adjusted net income of 2 percent. Consequently, the company revised its full-year 2026 guidance to reflect organic operational revenue growth between minus 3 percent and minus 1 percent, with adjusted net income growth expected to fall between minus 9 percent and minus 5 percent.
The mixed performance across business segments drove the outlook revision. While international revenue rose 6 percent and livestock revenue grew 11 percent, companion animal revenue declined by 6 percent due to competitive pressure and affordability concerns in key US categories. Diagnostics revenue provided a partial offset with a 12 percent increase during the quarter.
Zoetis declared a fourth-quarter 2026 dividend of USD 0.53 per share, payable on December 1, 2026, for shareholders of record on October 30, 2026. The company is scheduled to report its third-quarter 2026 results on November 5, 2026, which will test whether the revised full-year guidance holds amidst ongoing operating pressures.
π Goldman Sachs initiates coverage with Hold rating and USD 74 price target for Zoetis.
π° Q2 revenue hit USD 2.47 billion while adjusted net income declined 2%.
π Full-year organic revenue growth guidance revised to minus 3% to minus 1%.
π Companion animal revenue fell 6% due to competition and affordability issues.
Zoetis appointed Iris Knobloch to its board of directors on October 13, 2026, expanding the committee to 13 members effective December 1, 2026. The new director brings expertise in consumer strategy and digital transformation as the company navigates softer demand within its companion-animal segment.
Zoetis reported second-quarter 2026 revenue of USD 2.47 billion, while adjusted net income declined by 2 percent to USD 781 million. Consequently, the company reduced its full-year organic operational revenue guidance to a range between USD 9.12 billion and USD 9.32 billion, reflecting an expected decline of 1 percent to 3 percent.
Revenue performance was mixed geographically and by segment during the quarter. Revenue in the United States fell 7 percent, whereas international revenue grew 6 percent and the livestock segment expanded by 11 percent. The company faces a key test regarding whether companion-animal demand stabilizes before its third-quarter results release scheduled for November 5, 2026.
Zoetis maintains a market capitalization of USD 31.6 billion as of October 14, 2026. Despite the guidance cut, the stock traded at EUR 67.41 on October 15, 2026, showing resilience in value despite the revised outlook and wider 52-week trading range between USD 68.77 and USD 148.30.
The article compares Pfizer and Zoetis, focusing on their divergent strategies regarding branded medicines. While Pfizer is acquiring replacements for drugs losing exclusivity to drive growth, Zoetis is facing a price war where it must cut effective prices to retain its franchises. This strategic divergence has led to contrasting financial guidance: Pfizer raised its 2026 revenue midpoint by $500 million driven by underlying business growth, whereas Zoetis lowered its outlook expecting a 1% to 3% organic revenue decline.
Zoetis is currently navigating significant headwinds in its Companion Animal segment, which saw a 6% organic revenue drop in the second quarter of 2026, with Key Dermatology falling 16%. To combat new entrants using discounting and rebates, Zoetis has invested in gross-to-net strategies and adjusted prices on key products like Cerenia. Despite these challenges, the company maintains superior profitability with a 37.6% operating margin compared to Pfizer's core 26.7%, though Pfizer recently recorded $4.3 billion in noncash intangible asset impairments.
Valuation metrics show Zoetis trading at a significant discount relative to Pfizer on an unadjusted price-to-EBIT basis (9.2x vs 23.9x), although the gap narrows when accounting for Pfizer's impairment charges. Over the trailing three years, Zoetis has averaged 5.0% revenue growth against Pfizer's -5.2%, while Zoetis lost 50.8% of its stock value over the past twelve months compared to Pfizer's 21.1% gain. The analysis concludes that Zoetis represents a better business at a better price, provided investors can endure the ongoing price war dynamics.
π Zoetis lowered 2026 revenue outlook to 1%-3% organic decline due to lack of market stabilization visibility.
πΎ Companion Animal revenue fell 6% in Q2 2026, with Key Dermatology down 16%.
π Livestock and Companion Animal Diagnostics revenues grew 11% and 12% respectively in Q2 2026.
βοΈ Zoetis invests in gross-to-net to defend market share against rivals using discounting and bundling.
π Stock lost 50.8% over past twelve months while maintaining superior 37.6% operating margin.
π Zoetis lowered its 2026 revenue outlook to expect a 1% to 3% organic decline due to lack of market stabilization visibility.
π Pfizer raised its 2026 revenue guidance midpoint by $500 million, driven by underlying business growth excluding COVID products.
πΎ Zoetis reported a 6% organic decline in Companion Animal revenue for the second quarter of 2026, with Key Dermatology down 16%.
βοΈ Zoetis is engaging in price adjustments and gross-to-net investments to defend market share against rivals using discounting and bundling.
π Livestock revenue grew 11% and Companion Animal Diagnostics grew 12% for Zoetis in the second quarter of 2026 on an organic basis.
π° Zoetis maintains a superior operating margin of 37.6% compared to Pfizer's core 26.7% despite Pfizer's recent impairment charges.
π On an unadjusted price-to-EBIT basis, Zoetis trades at 9.2x versus Pfizer's 23.9x, narrowing to 9.0x and 9.7x respectively after impairments.
π Over three years, Zoetis has averaged 5.0% revenue growth while Pfizer has averaged -5.2% trailing performance.
π Zoetis stock lost 50.8% over the past twelve months, contrasting with Pfizer's 21.1% gain during the same period.
Zoetis (NYSE:ZTS) is presented as a specialized animal-health company that combines strong profitability with a discounted valuation relative to industry peers. The article argues that the stock's low earnings multiple is meaningful because it belongs to a business with durable returns on equity and invested capital, solid operating margins, and an established position in veterinary care markets.
The analysis highlights Zoetis' robust free cash flow generation and efficient capital use as key quality indicators that distinguish it from companies appearing cheap due to fundamental weakness. However, the report notes concerns regarding elevated leverage compared to industry standards and moderate growth rates, suggesting the market may be pricing in balance-sheet risks or slower expansion.
Long-term demand drivers for Zoetis include the growing importance of companion animals in household spending and the critical need for livestock health management in food production. The company's specialized portfolio of medicines, vaccines, and diagnostics creates barriers to entry, but investors are advised to monitor earnings durability, margin resilience, and debt levels to determine if the valuation discount will narrow.
π Zoetis trades at a lower earnings multiple than the animal-health industry.
π° Company generates robust returns on equity and invested capital efficiently.
π‘οΈ Strong operating margins provide a financial cushion against cost pressures.
β οΈ Leverage remains elevated relative to equity compared to much of the industry.
π Growth pace is moderate with measured rather than accelerating earnings expectations.
π Zoetis trades at a considerably lower earnings multiple than the broader animal-health industry while maintaining strong operating profitability.
π° The company generates robust returns on equity and invested capital, indicating efficient use of resources to generate operating returns.
π‘οΈ Strong operating margins provide a financial cushion against cost pressures and offer management flexibility during market changes.
π§ Zoetis has been recognized by quality screens for its strong free cash flow generation capabilities.
β οΈ Leverage remains a key concern as debt relative to equity is comparatively elevated against much of the industry.
π Growth pace is moderate compared to the strength of profitability, with forward expectations indicating measured rather than accelerating earnings growth.
πΎ Long-term demand drivers include increasing companion animal ownership and the necessity of livestock health for food production.
π High barriers to entry exist due to the need for scientific expertise, regulatory approvals, and established veterinary relationships.
π Investors should monitor earnings quality, margin resilience, and leverage reduction as key signals for future valuation reassessment.
Bullish Signals
Strong profitability paired with discounted valuation creates attractive setup.
Risk Factors
Leverage elevated relative to industry peers.
Growth moderate vs strong profitability.
Balance sheet risk from high debt.
Bullish Signals
Zoetis combines strong profitability with a discounted valuation, creating an attractive setup where a low multiple belongs to a company with durable operating quality.
The company generates robust returns on equity and invested capital, demonstrating the ability to produce substantial returns from deployed capital.
Strong operating margins provide a cushion against cost pressures and give management flexibility when navigating changes in demand or pricing.
Zoetis has been recognized by quality screens focused on free cash flow, reinforcing that its operating model produces meaningful cash resources.
The business benefits from long-term demand drivers such as the increasing importance of companion animals and livestock health needs.
Risk Factors
Leverage deserves careful monitoring as debt relative to equity is comparatively elevated against much of the industry.
Growth pace is moderate compared to the strength of profitability, with forward expectations indicating measured rather than accelerating earnings growth.
The company's financial structure is not without areas that deserve attention, specifically regarding balance-sheet risk and debt levels.
iA Global Asset Management Inc. significantly increased its stake in Zoetis Inc. (NYSE:ZTS) by 798.4% in the first quarter, purchasing an additional 42,059 shares to hold a total of 47,327 shares valued at $5.6 million. Several other institutional investors, including Global Wealth Strategies & Associates and Prosperity Bancshares Inc., also established new positions in the fourth quarter, while insider ownership remains low at 0.22% despite recent purchases by directors Michael B. Mccallister and Paul Bisaro totaling over $886,000 in the last ninety days.
Zoetis reported quarterly earnings on May 7th with revenue of $2.26 billion, representing a 2.9% year-over-year increase but missing analyst expectations by $0.07 per share. The company posted earnings per share of $1.53 against a consensus of $1.60, maintaining a strong return on equity of 66.85% and a net margin of 27.80%. Analysts have set full-year 2026 guidance between $6.85 and $7.00 EPS, slightly below the current consensus estimate of $6.87.
The stock currently trades with a market cap of $30.39 billion and a P/E ratio of 12.02, trading below its 50-day moving average of $85.77 and 200-day moving average of $109.95. Analyst sentiment is mixed, with recent downgrades from Wall Street Zen and JPMorgan Chase & Co., alongside a restated 'market perform' rating from Leerink Partners, resulting in a consensus 'Hold' rating and a price target of $126.92.
π iA Global raised Zoetis position by 798.4% to 47,327 shares.
π° Institutional holdings valued at $5.6 million as of latest period.
π Q1 revenue rose 2.9% but EPS missed estimates by $0.07.
π΅ EPS reached $1.53 with net margin of 27.80%.
π Quarterly dividend of $0.53 payable September 1st to record holders.
π iA Global Asset Management Inc. raised its Zoetis position by 798.4% in Q1, adding 42,059 shares to a total holding of 47,327 shares.
π° The company's institutional holdings are valued at $5,595,000 as of the end of the most recent reporting period.
π Zoetis reported Q1 revenue of $2.26 billion, a 2.9% increase year-over-year, but missed analyst EPS estimates by $0.07.
π΅ The company posted earnings per share of $1.53 with a return on equity of 66.85% and a net margin of 27.80%.
π Zoetis announced a quarterly dividend of $0.53 per share, payable on September 1st to shareholders of record on July 20th.
π The stock has a market cap of $30.39 billion and trades at a P/E ratio of 12.02.
π Recent analyst actions include downgrades from Wall Street Zen and JPMorgan Chase & Co., lowering price targets to $115.00 and $130.00 respectively.
π― The consensus analyst rating is 'Hold' with a 12-month price target of $126.92.
π Insider activity shows directors Michael B. Mccallister and Paul Bisaro increased their stakes by 13.94% and 7.73% respectively in May.
π Zoetis shares opened at $72.48, trading below its 50-day moving average of $85.77 and 200-day moving average of $109.95.
Bullish Signals
iA Global increased Zoetis position by 798.4% in Q1.
Zoetis achieved 66.85% return on equity and 27.80% net margin.
Revenue grew 2.9% year-over-year to reach $2.26 billion.
Insiders increased ownership stakes significantly in May.
Current ratio of 3.15 and quick ratio of 1.91.
Risk Factors
EPS missed by $0.07, reporting $1.53 vs $1.60 expected.
Revenue growth slowed to 2.9%, below analyst expectations.
Analysts downgraded stock; Zen and JPM lowered price targets.
Stock trades at $72.48, well below $85.77 50-day average.
Bullish Signals
iA Global Asset Management Inc. executed a massive 798.4% increase in its Zoetis position during Q1, signaling strong institutional confidence.
Zoetis achieved a robust return on equity of 66.85% and maintained a healthy net margin of 27.80% despite missing earnings estimates.
The company delivered solid revenue growth of 2.9% year-over-year, reaching $2.26 billion in the quarter.
Insiders have been active buyers, with directors increasing their ownership stakes significantly in May.
Zoetis maintains a strong balance sheet with a current ratio of 3.15 and a quick ratio of 1.91.
Risk Factors
Zoetis missed the quarterly earnings per share consensus estimate by $0.07, reporting $1.53 against expectations of $1.60.
Revenue growth slowed to 2.9% year-over-year, falling slightly short of analysts' expectations of $2.30 billion.
Recent analyst sentiment has turned cautious, with downgrades from Wall Street Zen and JPMorgan Chase & Co. lowering price targets.
The stock is trading significantly below its moving averages, currently at $72.48 versus a 50-day average of $85.77.
Zoetis (ZTS), the global leader in animal health, is facing a valuation re-rating as the market penalizes its stock for recent operational headwinds and a slowdown in demand. The company's shares have declined approximately 37% year-to-date and over 50% in twelve months, shifting investor perception from a flawless defensive growth play to a quality franchise entering a normalization phase.
The primary driver of this weakness is a significant slowdown in the United States market, where sales fell by 8% in the latest quarter, with companion animal revenue dropping 11%. Management attributes this decline to increased price sensitivity among pet owners, fewer veterinary visits, and lower demand for premium products. Consequently, Zoetis has revised its annual targets downward, projecting revenue between $9.68 billion and $9.96 billion.
Despite the U.S. struggles, international sales grew by 17%, and livestock exposure advanced by 15%, driven by cattle, poultry, swine, and fish sectors. The company maintains strong profitability with a diversified portfolio spanning parasiticides, vaccines, and dermatology. Analysts note that while growth visibility has deteriorated, the compression in valuation multiples makes Zoetis attractive for long-term investors seeking quality at a reasonable price.
Zoetis is leveraging its lower share price to accelerate capital allocation, increasing annualized share buybacks from $1.1 billion in 2024 to $3.2 billion in 2025 and raising total dividend distributions to $889 million. The stock's forward P/E ratio has compressed significantly from a high of 57x in 2021 to 20.9x for 2025, offering a compelling entry point for investors who believe the company can stabilize its U.S. growth and maintain its dominant market position.
π Shares dropped 37% YTD as valuation re-evaluates.
π° Q1 revenue fell 8% due to weak U.S. sales.
π International and livestock segments drove global growth.
π Guidance lowered to $9.68B-$9.96B annual revenue.
πΈ Buybacks accelerated from $1.1B to $3.2B annually.
π Zoetis shares have dropped approximately 37% since the beginning of the year and over 50% in twelve months as the market re-evaluates its premium valuation.
π° The company reported Q1 revenue of $2.26 billion, which was slightly below the consensus estimate of $2.30 billion due to an 8% decline in U.S. sales.
πΎ Companion animal revenue specifically fell by 11% driven by price sensitivity among pet owners and a decrease in veterinary visits.
π International operations provided a counterbalance with sales growth of 17%, while the livestock segment advanced by 15%.
π Zoetis lowered its annual revenue guidance to a range of $9.68 billion to $9.96 billion and adjusted EPS targets to $6.85 to $7.00.
π The forward P/E multiple has compressed from 57x in 2021 to 20.9x for 2025, reflecting a significant de-rating of the stock.
πΈ Management is accelerating share buybacks, increasing the annualized program from $1.1 billion in 2024 to $3.2 billion in 2025.
π The quarterly dividend remains at $0.53 per share, with total annual distributions rising to $889 million for 2025.
π¬ Zoetis maintains a dominant market position with franchises that have dominated specific segments for twenty to thirty years.
β οΈ The primary risks include intensifying competition in dermatology and antiparasitics, as well as potential margin pressure from generic products.
π¦ The company has issued convertible debt with a 0.25% coupon to finance its capital allocation strategy while limiting dilution.
π Future revenue is projected to grow steadily from $9.78 billion in 2026 to $10.65 billion in 2028 based on current forecasts.
Bullish Signals
Zoetis dominates segments with franchises stable for 20-30 years.
Companion animal segment drives nearly 68% of total revenue.
International sales surged 17% in the latest quarter.
Share buybacks increase from $1.1B in 2024 to $3.2B in 2025.
Total dividends rise to $889 million in 2025.
Net income grows from $2.49B in 2024 to $2.67B in 2025.
Forward P/E compresses to 20.9x for 2025 and 12.1x for 2026.
Risk Factors
U.S. sales fell 8%; companion revenue down 11%.
Revenue guidance revised to $9.68B-$9.96B; EPS cut.
Zoetis maintains a dominant market position with several franchises that have dominated their segments for twenty to thirty years, providing long-term stability.
The company possesses strong pricing power and exceptional profitability, particularly within the high-margin companion animal segment which accounts for nearly 68% of revenue.
International sales grew by 17% in the latest quarter, demonstrating that the company has pockets of growth outside the struggling U.S. market.
Management is aggressively returning capital to shareholders by increasing annualized share buybacks from $1.1 billion in 2024 to $3.2 billion in 2025.
The total dividend distribution is set to rise to $889 million in 2025, maintaining a quarterly payout of $0.53 per share for shareholders of record as of July 20, 2026.
Zoetis has secured financing through convertible debt with a low 0.25% coupon and mechanisms to limit potential dilution, supporting its capital allocation strategy.
Despite the slowdown, net income is expected to rise from $2.49 billion in 2024 to $2.67 billion in 2025 aided by further price increases.
The forward P/E ratio has compressed significantly to 20.9x for 2025 and is projected to reach 12.1x for 2026, offering a reasonable valuation for a high-quality franchise.
Risk Factors
U.S. sales fell by 8% in the latest quarter, with companion animal revenue declining by 11% due to increased price sensitivity and fewer veterinary visits.
Zoetis has been forced to lower its annual targets, revising revenue guidance to a range of $9.68 billion to $9.96 billion and reducing EPS expectations.
Operational organic revenue growth was flat in the latest quarter, marking a sharp change in pace for a stock previously appreciated for its consistency.
Competition is intensifying in dermatology and antiparasitics segments, while generic products are weighing on key franchises like Convenia and Cerenia.
The treatment Librela for osteoarthritis pain in dogs saw a decline, indicating potential weakness in specific high-value product lines.
The primary threat to the business model comes from competition, where generics and new entrants could erode the quasi-monopoly status of certain franchises.
Zoetis remains exposed to household budget trade-offs as the decline in veterinary visits shows that animal health is sensitive to consumer spending cuts.
Zoetis Inc. (NYSE: ZTS) is the subject of a newly filed securities fraud class action lawsuit in the U.S. District Court for the Southern District of New York, captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401 (S.D.N.Y.). The litigation alleges that the company and its executives made materially false or misleading statements regarding product adoption and business prospects during a specific class period.
The core allegations focus on four key areas: weakening prescription growth for Librela following FDA safety warnings about neurological complications; significant market share loss for Simparica Trio to lower-priced competitors; declining market share for dermatological products Apoquel and Cytopoint; and the assertion that management's positive outlook lacked a reasonable basis given these deteriorating fundamentals.
Financial context provided in the filing notes that on May 7, 2026, Zoetis reported first-quarter results showing significant declines in its Companion Animal business. This news triggered an immediate 21.5% drop in the company's stock price. Investors who purchased or acquired ZTS securities between January 14, 2025, and May 6, 2026, are invited to seek lead plaintiff status by July 27, 2026.
The press release, issued by law firm Kessler Topaz Meltzer & Check, LLP, outlines the process for investors to file for lead plaintiff status or remain absent class members. The firm operates on a contingency fee basis with no cost to investors for an initial case evaluation. The article serves as a formal notice of the lawsuit's existence and the opportunity for affected shareholders to participate in directing the litigation.
π Securities fraud lawsuit filed against Zoetis Inc. in Southern District of New York.
β³ Class period covers purchases from Jan 14, 2025 to May 6, 2026.
π Deadline to file for lead plaintiff status is July 27, 2026.
β οΈ Allegations include misstatements on Librela safety and Simparica Trio market share loss.
π° Stock dropped 21.5% after Q1 results showed Companion Animal business declines.
π A securities fraud class action lawsuit has been filed against Zoetis Inc. (ZTS) in the U.S. District Court for the Southern District of New York.
β³ The class period covers investors who purchased ZTS securities between January 14, 2025, and May 6, 2026.
π Investors have until July 27, 2026, to file for lead plaintiff status in the case.
β οΈ The complaint alleges material misstatements regarding product adoption and business prospects during the class period.
π Allegations include weakening growth for Librela following FDA safety warnings concerning serious neurological complications.
π Simparica Trio is accused of losing significant market share to lower-priced competitors in the flea, tick, and heartworm prevention space.
𧴠Dermatological products Apoquel and Cytopoint are alleged to be losing market share to competition.
π° Zoetis reported a 21.5% stock price decline on May 7, 2026, following first-quarter results showing significant declines in the Companion Animal business.
ποΈ The lawsuit is captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401 (S.D.N.Y.).
π Law firm Kessler Topaz Meltzer & Check, LLP is representing the class and offering free case evaluations on a contingency fee basis.
π₯ Investors may choose to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery.
π The filing asserts that management's statements about business operations lacked a reasonable basis given the alleged product struggles.
Risk Factors
Stock price fell 21.5% on May 7, 2026.
Librela growth weakening after FDA safety warnings.
Simparica Trio losing market share to cheaper rivals.
Apoquel and Cytopoint losing market share to competition.
Risk Factors
β οΈ The lawsuit alleges material misstatements and omissions regarding Zoetis's product adoption and business prospects during the class period.
π Allegations state that prescription growth for Librela was weakening following FDA safety warnings about serious neurological complications.
π Simparica Trio is accused of losing significant market share to lower-priced competitors, impacting revenue potential.
π Dermatological products Apoquel and Cytopoint are alleged to be losing market share to competition.
π The company's stock price fell 21.5% on May 7, 2026, following first-quarter results showing significant declines in the Companion Animal business.
β οΈ The complaint asserts that Defendants' statements about the company's business, operations, and prospects were materially false and misleading or lacked a reasonable basis.
A securities fraud class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) in the U.S. District Court for the Southern District of New York, alleging material misstatements regarding product adoption and business prospects between January 14, 2025, and May 6, 2026. The complaint asserts that defendants failed to disclose weakening prescription growth for Librela following FDA safety warnings concerning neurological complications, as well as significant market share losses for Simparica Trio and dermatological products like Apoquel and Cytopoint to lower-priced competitors.
The lawsuit highlights a specific catalyst where Zoetis reported its first quarter 2026 financial results on May 7, 2026, revealing a significant decline in its Companion Animal business. This news triggered an immediate 21.5% drop in the company's stock price. The legal filing contends that prior statements about the company's operations and future prospects were materially false or misleading at all relevant times during the class period.
Investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, are invited to contact Kessler Topaz Meltzer & Check, LLP by July 27, 2026, to seek lead plaintiff status or discuss recovery options. The firm operates on a contingency fee basis with no cost to investors for the initial case evaluation, while noting that Zoetis may retain counsel of choice or take no action.
π Lead plaintiff deadline is July 27, 2026 in Southern District of New York.
βοΈ Lawsuit alleges false claims about Librela growth and Simparica Trio market share losses.
π Stock fell 21.5% on May 7, 2026 due to Companion Animal business decline.
π£οΈ Defendants accused of making materially false statements without reasonable basis during class period.
π Contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation today.
π A securities fraud class action lawsuit against Zoetis Inc. (ZTS) is active in the Southern District of New York with a July 27, 2026 deadline for lead plaintiff status.
βοΈ The complaint alleges material misstatements regarding product adoption, specifically citing weakening growth for Librela due to FDA safety warnings and market share losses for Simparica Trio, Apoquel, and Cytopoint.
π Zoetis reported a significant decline in its Companion Animal business in the first quarter of 2026, causing its stock price to fall 21.5% on May 7, 2026.
π£οΈ Defendants are accused of making materially false statements about the company's business operations and prospects that lacked a reasonable basis during the class period.
π Investors can contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation regarding potential recovery options without cost or obligation.
Risk Factors
Lawsuit alleges false statements about product adoption and prospects.
Companion Animal business decline caused 21.5% stock drop on May 7, 2026.
Librela prescription growth weakening after FDA safety warnings.
Simparica Trio losing market share to lower-priced competitor.
Apoquel and Cytopoint losing market share to competition.
Risk Factors
β οΈ The lawsuit alleges that Zoetis made materially false and misleading statements concerning the company's product adoption and business prospects during the class period.
π Zoetis reported a significant decline in its Companion Animal business in Q1 2026, which directly caused the stock price to drop 21.5% on May 7, 2026.
β οΈ The complaint asserts that prescription growth for Librela was weakening following FDA safety warnings regarding serious neurological complications.
π Simparica Trio is alleged to be losing significant market share to a lower-priced competitor, impacting revenue stability.
β οΈ Dermatological products Apoquel and Cytopoint are accused of losing market share to competition, further undermining the company's growth narrative.
Banque Transatlantique SA reduced its stake in Zoetis Inc. (NYSE:ZTS) by 26.2% during the fourth quarter, selling 62,912 shares to hold a remaining position of 176,793 shares valued at $22.24 million. While Banque Transatlantique trimmed its exposure, several other institutional investors increased their holdings, including MidFirst Bank which established a new $633,000 position, and Pacer Advisors Inc. which boosted its stake by 18.3% to own 141,883 shares.
T. Rowe Price Investment Management Inc. significantly expanded its Zoetis position by 3,311.3%, acquiring an additional 153,611 shares worth $19.91 million, while Strive Financial Group LLC and Beacon Pointe Advisors LLC also added to their stakes. Collectively, hedge funds and other institutional investors own 92.80% of the company's outstanding stock, indicating strong institutional interest despite the reduction by Banque Transatlantique.
Zoetis recently reported fourth-quarter earnings of $1.53 per share, missing analyst consensus estimates of $1.60 by $0.07. The company generated revenue of $2.26 billion, which was 2.9% higher than the prior year but slightly below the expected $2.30 billion. Despite the miss, Zoetis maintained a strong return on equity of 66.85% and a net margin of 27.80%, with management providing full-year 2026 guidance for EPS between $6.85 and $7.00.
The company announced a quarterly dividend of $0.53 per share, payable on September 1st to stockholders of record as of July 20th, representing an annualized yield of 2.7%. Recent insider activity includes Director Frank A. Damelio purchasing 6,650 shares for $501,343 and Director Michael B. Mccallister buying 3,000 shares for $233,280, totaling $886,380 in insider purchases over the last three months. Analyst ratings remain mixed with a consensus target price of $133.92, though recent downgrades from Wall Street Zen and Stifel Nicolaus have tempered bullish sentiment.
π Banque Transatlantique sold shares, retaining a $22.24M stake.
π T. Rowe Price added 153,611 shares worth $19.91M.
π΅ Company declared $0.53 dividend with 35.16% payout ratio.
π Banque Transatlantique SA reduced its Zoetis stake by 26.2% in Q4, selling 62,912 shares while retaining 176,793 shares valued at $22.24 million.
π T. Rowe Price Investment Management Inc. increased its position by 3,311.3%, acquiring 153,611 additional shares worth $19.91 million in the fourth quarter.
π° MidFirst Bank established a new Zoetis position valued at approximately $633,000 during the same reporting period.
π Zoetis reported Q4 earnings of $1.53 EPS, missing analyst estimates of $1.60 by $0.07 despite revenue growth of 2.9% year-over-year.
π΅ The company declared a quarterly dividend of $0.53 per share with an ex-dividend date of July 20th and a payout ratio of 35.16%.
π Corporate insiders purchased 11,650 shares valued at $886,384 in the last three months, including significant buys by Directors Frank A. Damelio and Michael B. Mccallister.
π Analyst sentiment is mixed with a consensus target price of $133.92, following recent downgrades from Wall Street Zen and Stifel Nicolaus to 'Hold' ratings.
π’ Institutional ownership remains high at 92.80%, with other investors like Pacer Advisors boosting stakes by 18.3%.
Bullish Signals
T. Rowe Price increased stake by over 3,300%.
Insiders bought $886,384 worth in last three months.
Revenue grew 2.9% year-over-year to reach $2.26 billion.
Return on equity stands at robust 66.85%.
MidFirst Bank initiated new position valued at $633,000.
Risk Factors
EPS of $1.53 missed $1.60 estimate by $0.07.
Revenue of $2.26B fell short of $2.30B target.
Analysts downgraded stock to 'Hold' due to caution.
Banque Transatlantique reduced stake by 26.2%.
Bullish Signals
T. Rowe Price Investment Management Inc. aggressively increased its Zoetis stake by over 3,300%, acquiring more than 150,000 shares in a single quarter.
Corporate insiders have been net buyers, purchasing $886,384 worth of stock in the last three months, signaling confidence from management and directors.
Zoetis achieved revenue growth of 2.9% year-over-year to reach $2.26 billion, demonstrating continued top-line expansion despite a slight earnings miss.
The company maintains a robust return on equity of 66.85% and a healthy net margin of 27.80%, indicating strong operational profitability.
MidFirst Bank initiated a new position in Zoetis valued at $633,000, adding to the list of institutional investors increasing or starting exposure.
Risk Factors
Zoetis reported fourth-quarter earnings of $1.53 per share, which missed the consensus analyst estimate of $1.60 by $0.07.
Quarterly revenue of $2.26 billion fell short of analyst expectations of $2.30 billion, indicating a slight shortfall in performance.
Recent analyst downgrades from Wall Street Zen and Stifel Nicolaus have lowered the stock's rating to 'Hold', reflecting cautious sentiment.
Banque Transatlantique SA significantly reduced its stake by 26.2%, selling over 62,000 shares during the fourth quarter.
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc. following the company's announcement on May 7, 2026, of flat Q1 net income and a lowered full-year profit forecast. The stock price subsequently dropped 21.5% after Zoetis cited a challenging environment characterized by reduced veterinary visits and softer demand.
The lawsuit alleges securities fraud or other unlawful business practices committed by Zoetis and its officers or directors. Investors who purchased Zoetis shares during the class period are invited to join the lawsuit, with a deadline of July 27, 2026, to file their claims.
This legal action arises directly from the negative market reaction to Zoetis' financial performance, specifically the flat quarterly earnings and the downward revision of its annual profit guidance. The case highlights investor concerns regarding the company's reported business conditions in the veterinary sector.
βοΈ Pomerantz LLP filed a securities fraud class action against Zoetis Inc.
π Stock dropped 21.5% after flat Q1 income and lowered profit forecast.
πΎ Weak results blamed on reduced vet visits and softer market demand.
π Class period investors must join the lawsuit by July 27, 2026.
βοΈ Pomerantz LLP filed a class action lawsuit against Zoetis Inc. alleging securities fraud or unlawful business practices.
π Zoetis stock price fell 21.5% following the May 7, 2026, announcement of flat Q1 net income and lowered full-year profit forecast.
πΎ The company cited a challenging environment with reduced veterinary visits and softer demand as reasons for the weak results.
π Investors who bought shares during the class period have until July 27, 2026, to join the lawsuit.
π The legal case specifically targets Zoetis Inc. and its officers or directors regarding the reported financial performance.
Risk Factors
Profit forecast lowered for remainder of year.
Stock price dropped 21.5% after earnings.
Class action lawsuit alleges management fraud.
Risk Factors
π The company lowered its full-year profit forecast, signaling reduced expectations for the remainder of the year.
π Stock price dropped 21.5% immediately following the earnings announcement, reflecting significant negative market sentiment.
βοΈ A class action lawsuit has been filed alleging securities fraud or unlawful business practices by the company's management.
Kaplan Fox & Kilsheimer LLP has issued an alert regarding a securities class action lawsuit filed against Zoetis Inc. (NYSE: ZTS) on behalf of investors who acquired the company's securities between January 14, 2025 and May 6, 2026. The complaint alleges that Zoetis misled investors by portraying its Companion Animal segment as a durable growth engine driven by expanding markets and strong veterinarian adoption, while allegedly concealing serious safety concerns, intensifying competition, and declining veterinarian confidence that were eroding sales growth and financial outlook.
The lawsuit claims the full extent of these issues was revealed on May 7, 2026, when Zoetis reported first quarter 2026 financial results showing significant deterioration in its core Companion Animal business and sharply reduced full-year guidance. Following this announcement, Zoetis stock fell $23.91 per share, or 21.5%, to close at $87.31 per share on that date. The complaint asserts that throughout the class period, defendants knew or recklessly disregarded that veterinarian prescription growth for Librela was weakening due to FDA safety warnings regarding serious neurological complications in dogs, Simparica Trio was losing market share to a lower-priced competitor with broader indicated use, and dermatology products Apoquel and Cytopoint were losing substantial market share to a newly launched competing canine treatment.
Investors who suffered losses during the class period are encouraged to contact Kaplan Fox via email at [email protected] or by calling (646) 315-9003 for more information about the lead plaintiff process. Members of the proposed class may move the court no later than July 27, 2026 to serve as a lead plaintiff, though participation in that role is not required to share in any possible recovery. The firm notes that contacting them does not create an attorney-client relationship or an obligation to retain the client, and this press release may be considered attorney advertising in some jurisdictions.
π Class action filed against Zoetis for securities bought Jan 14, 2025 to May 6, 2026.
βοΈ Lawsuit alleges misleading claims about Companion Animal growth while hiding safety risks.
π Stock dropped 21.5% after revealing core business deterioration and market share losses.
ποΈ Investors can apply to be lead plaintiff by July 27, 2026.
π Contact Kaplan Fox & Kilsheimer LLP at (646) 315-9003 for representation.
π A class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) on behalf of investors who purchased securities between January 14, 2025 and May 6, 2026.
βοΈ The complaint alleges that Zoetis misled investors by portraying its Companion Animal segment as a durable growth engine while concealing serious safety concerns and declining veterinarian confidence.
π Stock prices fell $23.91 per share, or 21.5%, to close at $87.31 on May 7, 2026, following the disclosure of significant deterioration in the core Companion Animal business.
β οΈ Defendants are accused of knowing or recklessly disregarding that veterinarian prescription growth for Librela was weakening due to FDA safety warnings regarding neurological complications in dogs.
π Zoetis' Simparica Trio is alleged to be losing significant market share to a lower-priced competitor with broader indicated use in a slowing overall market.
π The company's dermatology products, Apoquel and Cytopoint, are accused of losing substantial market share to a newly launched competing canine treatment.
ποΈ Class members may move the court no later than July 27, 2026 to serve as a lead plaintiff for the purported class.
π Investors suffering losses can contact Kaplan Fox & Kilsheimer LLP via email at [email protected] or by calling (646) 315-9003.
βοΈ Kaplan Fox is a national law firm with over 50 years of experience in securities litigation and offices in New York, Oakland, Los Angeles, Chicago, and New Jersey.
π This press release may be considered Attorney Advertising in some jurisdictions under applicable law and ethical rules.
π€ Contacting or submitting information to Kaplan Fox does not create an attorney-client relationship nor an obligation to retain the client.
π More information about the case is available at www.kaplanfox.com/case/zoetis-inc-class-action-alert-learn-more-now/.
A securities class action lawsuit alleges Zoetis misled investors by concealing serious safety concerns, intensifying competition, and declining veterinarian confidence that were eroding sales growth and financial outlook.
Zoetis' flagship product Librela faced sharply weakening prescription growth due to FDA safety warnings regarding serious neurological complications in dogs.
Simparica Trio is losing significant market share to a lower-priced competitor with broader indicated use in a slowing overall market.
Dermatology products Apoquel and Cytopoint are losing substantial market share to a newly launched competing canine treatment.
First quarter 2026 financial results showed significant deterioration across the core Companion Animal business, leading to sharply reduced full-year guidance.
Zoetis stock fell $23.91 per share, or 21.5%, to close at $87.31 per share on May 7, 2026 following the announcement of deteriorating results.
Zoetis Inc. (ZTS) has experienced a significant decline of over 50% in its share price over the past year, creating what analysts view as a potential deep value opportunity for long-term dividend growth investors. The company's underperformance is attributed to persistent inflationary pressures, reduced demand from U.S. companion animal owners, and heightened competition within the veterinary pharmaceutical sector, which have led to revised guidance for 2026 and a recent sell-off in the stock.
Despite these headwinds, Zoetis maintains a robust balance sheet with a well-covered dividend at a 39% payout ratio and continues to execute ongoing share buybacks, supporting long-term shareholder value. The stock currently trades at a forward price-to-earnings multiple of 11.5x, which is notably lower than both its peers and historical averages, suggesting over 60% upside potential for investors willing to hold through near-term volatility.
Analysts maintain a hold rating on the stock due to macroeconomic risks and continued near-term pressures, though they emphasize that the fundamental business remains strong. The article notes that while the business may not fit every investment style, the valuation gap presents an attractive entry point for those focused on quality blue-chip stocks with reliable dividend growth potential.
π ZTS shares dropped over 50% due to inflation, weak demand, and revised guidance.
π° Strong balance sheet supports a covered dividend at a 39% payout ratio.
π Valuation sits at 11.5x forward P/E with analysts projecting over 60% upside.
π Zoetis (ZTS) shares have declined over 50% in the past year, creating a potential entry point for long-term dividend growth investors.
π The stock's underperformance is attributed to persistent inflation, reduced U.S. companion animal demand, and heightened competition.
π These headwinds led management to revise its 2026 guidance downward, contributing to the recent sell-off.
π° Despite market pressures, Zoetis maintains a strong balance sheet with a well-covered dividend at a 39% payout ratio.
π The company is also executing ongoing share buybacks to support long-term shareholder value.
π Valuation metrics show a forward P/E of 11.5x, which is significantly below both peer averages and historical levels.
π Analysts suggest the stock offers over 60% upside potential based on current valuation gaps.
β οΈ However, macroeconomic risks and near-term operational pressures warrant a cautious hold rating rather than an immediate buy.
π The article is written by a dividend-focused investor who prefers quality blue-chip stocks and BDCs.
π‘οΈ The author discloses no current stock positions or plans to initiate trades in the mentioned companies within 72 hours.
βοΈ Seeking Alpha notes that past performance does not guarantee future results and this is not personalized investment advice.
Zoetis Inc. (ZTS) declared a third-quarter 2026 cash dividend of $0.53 per share on May 20, 2026. The dividend is scheduled to be paid on September 1, 2026, to shareholders of record as of the close of business on July 20, 2026. This decision highlights Zoetis's commitment to returning capital to shareholders and reflects confidence in its financial position and cash generation capabilities.
Analyst ratings for ZTS stock show a Buy rating with a $112.00 price target, while TipRanks' AI Analyst gives it a Neutral score due to strong profitability offset by weak technicals and mixed earnings commentary. Zoetis is the world's leading animal health company focused on advancing care for animals, providing medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions to veterinarians, livestock producers, and pet owners in more than 100 countries.
πΎ Strong global growth offsets weakness in the U.S. companion-animal sector.
π Zoetis Inc. (ZTS) declared a third-quarter 2026 cash dividend of $0.53 per share on May 20, 2026.
π° The dividend is scheduled to be paid on September 1, 2026, to shareholders of record as of July 20, 2026.
π€ This payout reflects the company's commitment to returning capital and demonstrates confidence in its financial position.
π Analysts maintain a Buy rating on ZTS with an average price target of $112.00.
βοΈ TipRanks' AI Analyst Spark rates ZTS as Neutral due to strong profitability offset by weak technicals and mixed earnings commentary.
πΎ Zoetis faces positive full-year guidance and strong international execution but contends with weakness in the U.S. companion-animal sector.
π The company operates in over 100 countries, serving veterinarians, livestock producers, and pet owners with medicines, vaccines, and diagnostics.
π’ Listed on the NYSE as ZTS, Zoetis is the world's leading animal health company with nearly 75 years of experience.
π The dividend decision underscores income visibility for investors and highlights the company's cash generation capacity.
β οΈ Valuation is considered supportive but not compelling enough to outweigh near-term demand risks according to Spark's analysis.
Bullish Signals
Zoetis declared Q3 2026 dividend of $0.53/share.
Regular dividends provide income visibility for investors.
Analysts rate ZTS Buy with $112 target.
Leading animal health firm operates in 100+ countries.
Risk Factors
U.S. companion-animal sales weakness offsets strong performance.
Competitive uncertainty hinders stock technicals and demand.
Price trades below moving averages with negative momentum.
Bullish Signals
Zoetis declared a third-quarter 2026 cash dividend of $0.53 per share, demonstrating confidence in its financial position and cash generation capacity.
The company's ongoing commitment to returning capital to shareholders through regular dividends provides income visibility for investors.
Analysts maintain a Buy rating on ZTS with a price target of $112.00, reflecting strong underlying profitability and cash generation.
Zoetis is the world's leading animal health company operating in more than 100 countries, leveraging data-driven R&D and advanced manufacturing.
Risk Factors
Analyst commentary notes meaningful weakness in U.S. companion-animal sales, which offsets strong performance elsewhere.
Competitive uncertainty is explicitly cited as a factor holding back the stock's technicals and near-term demand outlook.
Weak technical indicators show the price trading well below key moving averages with negative momentum.
Zoetis (ZTS) reported a challenging first quarter of 2026, missing Wall Street expectations on revenue and earnings due to increased price sensitivity among pet owners, lower veterinary clinic traffic, and intensified competition. Revenue came in at $2.26 billion versus analyst estimates of $2.31 billion, representing a 2.9% year-on-year growth but a 2.1% miss against consensus. Adjusted EPS was $1.53 compared to expectations of $1.62, and Adjusted EBITDA reached $985.9 million against estimates of $1.05 billion. The company also lowered its full-year revenue guidance to $9.82 billion at the midpoint from $9.93 billion and reduced its full-year Adjusted EPS guidance to $6.93 at the midpoint, a 1.8% decrease. Operating margins declined to 35.4% from 36.9% in the prior year quarter.
Management attributed the underperformance to aggressive pricing by competitors, new market entrants compressing growth in dermatology and parasiticide franchises, and unfavorable weather conditions like winter storms that reduced clinic visits. CEO Kristin Peck emphasized that the quarter unfolded differently than expected, particularly in the companion animal segment. During the earnings call, analysts questioned the sustainability of competitive pressures and strategies to address affordability concerns. CFO Wetteny Joseph clarified that guidance assumes continued headwinds with no immediate rebound in distributor inventory, attributing stabilization to easier comparables and direct commercial actions rather than channel dynamics.
The company plans to maintain its premium positioning through selective promotional activity while enhancing point-of-sale loyalty and affordability programs for pet owners rather than broadly lowering product prices. Analysts noted that demand for veterinary care remains structurally strong with long-term stabilization expected as price-driven promotions normalize. Key areas of focus for upcoming quarters include stabilizing U.S. companion animal sales, the trajectory of new product launches such as long-acting monoclonal antibodies and the integration of Neogenβs genomics business, and continued momentum in livestock and diagnostics. Progress on cost discipline and portfolio optimization will also be critical for gauging execution.
βοΈ Weather storms and price sensitivity drove lower clinic traffic and sales.
πΎ Guidance cut for full-year due to companion animal headwinds.
π Livestock segments will offset weak growth in dermatology and parasiticide.
π¬ Future focus on new launches and loyalty programs to stabilize demand.
π Zoetis (ZTS) reported Q1 2026 revenue of $2.26 billion, missing analyst estimates of $2.31 billion by 2.9%.
π° Adjusted EPS came in at $1.53, falling short of the $1.62 consensus expectation by 5.3%.
π Operating margins declined to 35.4% from 36.9% year-over-year as competitive pressures intensified.
π Management lowered full-year revenue guidance to a midpoint of $9.82 billion, down 1.1% from the prior $9.93 billion target.
π Full-year Adjusted EPS guidance was reduced to $6.93 at the midpoint, representing a 1.8% decrease.
πΎ CEO Kristin Peck attributed the miss to price sensitivity among pet owners and lower veterinary clinic traffic.
βοΈ Unfavorable weather conditions, including winter storms, further compounded headwinds by reducing clinic visits.
π Growth was particularly compressed in dermatology and parasiticide franchises due to aggressive pricing and new market entrants.
π CFO Wetteny Joseph clarified that guidance assumes continued headwinds with no immediate rebound in distributor inventory.
π‘οΈ Management plans to maintain premium positioning while engaging in selective promotional activity rather than broad price cuts.
π³ Zoetis is enhancing point-of-sale loyalty and affordability programs to address consumer budget constraints without lowering product prices.
π Livestock segments are expected to continue driving momentum while U.S. companion animal growth faces headwinds.
π¬ Upcoming strategic focus includes new product launches like long-acting monoclonal antibodies and Neogenβs genomics integration.
π The stock price dropped significantly from $111.22 pre-earnings to $74.55 following the disappointing results.
π’ Market capitalization stands at $31.17 billion as investors react to the challenging first quarter performance.
Bullish Signals
CEO Peck targets share stabilization and affordability to ease competitive pressure.
Management sees strong structural demand as price promotions normalize.
CFO Joseph notes livestock momentum despite continued headwinds.
Company boosts loyalty programs instead of lowering prices for premium positioning.
New launches like monoclonal antibodies and Neogen integration are key catalysts.
Risk Factors
Zoetis missed revenue and earnings estimates by 2.1%.
Full-year guidance lowered for revenue and Adjusted EPS.
Operating margins fell due to competitor pricing pressure.
CFO cites distributor inventory headwinds with no immediate rebound.
Analysts question competitive pressure sustainability and affordability strategies.
Bullish Signals
CEO Kristin Peck emphasized ongoing share stabilization in key franchises and targeted affordability initiatives to address competitive pressures.
Management insists that demand for veterinary care remains structurally strong, with long-term stabilization expected as price-driven promotions normalize.
CFO Wetteny Joseph clarified that guidance assumes continued headwinds but highlighted livestock driving momentum in the portfolio.
The company is enhancing point-of-sale loyalty and affordability programs for pet owners rather than broadly lowering product prices to maintain premium positioning.
Upcoming catalysts include new product launches, particularly long-acting monoclonal antibodies and the integration of Neogen's genomics business.
Progress on cost discipline and portfolio optimization will be critical for gauging execution in upcoming quarters.
Risk Factors
Zoetis missed Wall Street expectations on revenue and earnings, with revenue of $2.26 billion versus analyst estimates of $2.31 billion (a 2.1% miss) and Adjusted EPS of $1.53 versus expectations of $1.62.
The company lowered its full-year revenue guidance to $9.82 billion at the midpoint from $9.93 billion and reduced its full-year Adjusted EPS guidance to $6.93 at the midpoint, a 1.8% decrease.
Operating margins declined to 35.4% from 36.9% in the prior year quarter due to aggressive pricing by competitors and new market entrants compressing growth in dermatology and parasiticide franchises.
CFO Wetteny Joseph clarified that guidance assumes continued headwinds with no immediate rebound in distributor inventory, attributing stabilization to easier comparables rather than channel dynamics.
Analysts questioned the sustainability of competitive pressures and strategies to address affordability concerns, indicating ongoing market challenges.
Analyst sentiment remains mixed for a trio of healthcare sector companies, with Zoetis (ZTS) receiving the most positive attention. Erin Wright at Morgan Stanley maintained a Buy rating on ZTS, setting a price target of $115.00 against a share price closing at $75.48 last Thursday. TipRanks data indicates a moderate buy consensus for ZTS with an average analyst price target of $132.58, suggesting 78.1% upside from current levels; this follows a previous Buy upgrade by xAI in late April to a $127.00 target. Gavin Clark-Gartner at Evercore ISI holds Sarepta Therapeutics (SRPT) with a price target of $19.00, while the broader analyst consensus rates SRPT as Hold with an average target of $21.64, implying 12.0% upside from the closing price of $18.68.
For GoodRx Holdings (GDRX), Jailendra Singh at Truist Financial maintains a Hold rating with a price target of $3.09, which represents 18.4% upside from its Thursday closing price of $2.49. The consensus for GDRX remains Hold according to TipRanks data. The article notes that these insights come via TipRanks, aggregating analyst actions and targets for the three healthcare names, highlighting divergent expectations within the broader Healthcare sector coverage today.
π₯ Mixed analyst sentiment covers Zoetis, Sarepta Therapeutics, and GoodRx.
π° Zoetis commands a Buy rating with $115-$132.58 price targets.
β οΈ Sarepta and GoodRx hold consensus ratings of 12-18% upside potential.
π Recent AI-driven upgrades and downgrades influenced these stock valuations.
π₯ Analysts show mixed sentiment on three healthcare companies: Zoetis (ZTS), Sarepta Therapeutics (SRPT), and GoodRx Holdings (GDRX).
π° Morgan Stanley maintained a Buy rating on Zoetis with a $115.00 price target, up from its Thursday close of $75.48.
π The Street consensus for Zoetis is Moderate Buy with an average price target of $132.58, implying 78.1% upside.
β οΈ Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating on Sarepta Therapeutics with a $19.00 price target.
π― Sarepta Therapeutics consensus remains Hold with an average price target of $21.64, suggesting 12.0% upside.
πΉ Truist Financial analyst Jailendra Singh maintained a Hold rating on GoodRx Holdings at its Thursday close of $2.49.
π The analyst consensus for GoodRx is Hold with a $3.09 price target, implying 18.4% potential upside.
β‘ Recent upgrades and downgrades from firms like TipRanks β xAI and DeepSeek have influenced the price targets for SRPT and GDRX.
Bullish Signals
Analysts maintain Buy rating on Zoetis (ZTS) with average target $132.58.
Erin Wright from Morgan Stanley maintains Buy on Zoetis at $115.00.
TipRanks rates Erin Wright as a 5-star analyst with 14.7% returns.
Zoetis has higher implied upside than Sarepta or GoodRx.
Risk Factors
Analyst consensus is Hold with price target of $21.64, implying only 12% upside.
Bullish Signals
Analysts maintain a Buy rating on Zoetis (ZTS) with an average price target of $132.58, representing a 78.1% upside from current levels.
Erin Wright from Morgan Stanley maintained a Buy rating on Zoetis with a specific price target of $115.00, which is significantly above the recent closing price of $75.48.
TipRanks highlights that Erin Wright is a 5-star analyst with an impressive average return of 14.7% and a 62.5% success rate covering Healthcare stocks.
TipRanks upgraded Zoetis to Buy with a $127.00 price target in a report issued on May 6, reinforcing positive momentum for the stock.
Analyst consensus on Sarepta Therapeutics (SRPT) shows a Hold rating with an average price target of $21.64, implying a 12.0% upside from current levels.
Sarepta Therapeutics received a Hold upgrade with a $22.50 price target in a report issued on May 5 by TipRanks β xAI.
GoodRx Holdings (GDRX) has an analyst consensus of Hold with a price target of $3.09, implying a 18.4% upside from current levels.
The stock market generally favors Zoetis over Sarepta Therapeutics and GoodRx Holdings based on analyst buy ratings and higher implied upside potential.
Risk Factors
Analyst Erin Wright from Morgan Stanley maintains a Buy rating with a price target of $115.00, yet the company's shares closed last Thursday at $75.48, suggesting significant downside potential remains even with bullish analyst coverage.
The analyst consensus for Sarepta Therapeutics is a Hold with an average price target of $21.64, implying only 12.0% upside from current levels, indicating limited growth expectations among investors.
Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating on Sarepta Therapeutics today and set a price target of $19.00, nearly flat with the company's closing price of $18.68.
Truist Financial analyst Jailendra Singh has zero stars on TipRanks.com and an average return of -12.4% over his career, raising concerns about the reliability of coverage on GoodRx Holdings despite a Hold rating.
GoodRx Holdings has an analyst consensus of Hold with a price target of $3.09, yet recent downgrades to a $3.00 price target suggest growing skepticism among analysts regarding its future performance.
The article notes that the investor sentiment toward Tech stocks is overly optimistic ('partying like it's 1999'), suggesting potential market risk for healthcare companies as investors may overreact to positive earnings data.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)